Whether you have been diagnosed with atherosclerosis or you are simply concerned about your cardiovascular health, you may be interested to learn more about the legal process of getting Tasigna Lawyer. This article will provide you with an overview of what you need to know. It will also discuss the factors that affect how much compensation you may be entitled to.

Legal process

Several lawsuits have been filed against Tasigna by patients who suffered serious side effects after taking the drug. They claim the manufacturer, Novartis, knew about the risks of using the drug and did not warn patients.

The lawsuits allege that Tasigna causes atherosclerosis, or a thickening of the walls of the arteries. This can lead to a blood clot, which can cause severe medical problems.

Tasigna is a kinase inhibitor that is used to treat Philadelphia chromosome positive chronic myeloid leukemia. Chronic myeloid leukemia is a blood cancer that involves the unchecked spread of bone marrow tissue into the bloodstream. It affects about 51,500 people in the United States.

Tasigna was approved by the Food and Drug Administration in 2007. The drug is marketed as a prescription medication and is sold at a number of specialty pharmacies. However, Novartis is being accused of illegally marketing the drug and failing to warn users of the risks.

Compensation for atherosclerosis

Whether you've been injured by Tasigna, or your loved one has died after taking the drug, you may be entitled to compensation. Contact a Tasigna attorney today to discuss your options.

Tasigna is a cancer drug manufactured by Novartis Pharmaceuticals. It belongs to the tyrosine kinase inhibitor family and works by inhibiting the growth of blood cancer cells. But it's also been linked to atherosclerosis, which is a disease that causes plaque to build up in the arteries. This can cause the arteries to narrow, which decreases blood flow to the heart, brain, and other parts of the body. It can also lead to heart attacks, strokes, and other life-threatening complications.

According to an article published in the American Journal of Hematology, Tasigna may have caused the sudden aggravation of atherosclerosis in some patients. In addition, three patients had to undergo multiple surgeries because of Tasigna-induced peripheral arterial occlusive disease.

Tasigna is an important medicine in the treatment of chronic myeloid leukemia, a disease that originates in the bone marrow and then enters the bloodstream. It is one of the top ten cancer drugs in the world, and its sales totaled over $1.7 billion in 2016. But it's also been linked to atherosclerosis, a disease that causes plaque to build up inside the arteries.

Liability for atherosclerosis

Taking a drug like Tasigna can have a number of side effects. One of these side effects is atherosclerosis, or more commonly known as plaque buildup in the arteries. Plaque narrows the arteries, which can lead to a number of health issues, including heart disease and chronic kidney disease.

Despite the fact that the drug was marketed in the United States, there has been no official warning from Novartis about the risk of atherosclerosis. This is not the first time that Novartis has been in legal hot water. In fact, the company settled a lawsuit in 2015 alleging that Tasigna caused a stroke in a patient. The company is also facing lawsuits from patients who allegedly suffered from adverse reactions to the drug.

One of the most intriguing Tasigna lawsuits, though, involves the manufacturer's alleged failure to warn of the risk of atherosclerosis, a condition that can result in a stroke. This is a major reason why attorneys are suing Novartis over the product.

Side effects

Taking Tasigna may cause you to suffer from a number of side effects. These side effects may include nausea, vomiting, diarrhea, fatigue, night sweats, and a decreased blood count. In addition, Tasigna is also associated with a risk of a life-threatening condition called atherosclerosis. This condition affects the walls of blood vessels and can cause heart attacks, strokes, and amputations.

Tasigna is a drug approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia, a cancer that affects blood cells. It works by blocking proteins that allow cancer cells to grow.

Tasigna was also used to treat chronic myelogenous leukemia, and has been linked to the development of atherosclerosis. This condition is caused by the build-up of fats and cholesterol on the walls of artery. These fatty deposits cause the walls to thicken and restrict blood flow. It is also associated with obesity.

The FDA has yet to issue a formal recall of Tasigna. Nevertheless, there have been several studies that have linked Tasigna to atherosclerosis. These studies found that Tasigna users had a significantly higher risk of developing the condition.